相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Characterization of ibrutinib as a non-covalent inhibitor of SRC-family kinases
Ming Guo et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)
FGFR-TKI resistance in cancer: current status and perspectives
Sitong Yue et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor
Liangxing Wu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors
Francesco Facchinetti et al.
CLINICAL CANCER RESEARCH (2020)
Recent advance in the development of novel, selective and potent FGFR inhibitors
Feng-Tao Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4
Robin A. Fairhurst et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Development of a Potent and Specific FGFR4 Inhibitor for the Treatment of Hepatocellular Carcinoma
Renata Rezende Miranda et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
TAS-120 Overcomes Resistance to ATP-Compartitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholanjiocarcinoma
Lipika Goyal et al.
CANCER DISCOVERY (2019)
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Y. Loriot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer
Andreas Weiss et al.
MOLECULAR CANCER THERAPEUTICS (2019)
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
Richard D. Kim et al.
CANCER DISCOVERY (2019)
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma
Megan A. Hatlen et al.
CANCER DISCOVERY (2019)
Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects
Xiaoyun Lu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Fibroblast growth factor receptors as treatment targets in clinical oncology
Masaru Katoh
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4
Zhan Zhou et al.
CHEMICAL COMMUNICATIONS (2019)
The Cysteinome of Protein Kinases as a Target in Drug Development
Apirat Chaikuad et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2018)
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations
Sumanta K. Pal et al.
CANCER DISCOVERY (2018)
LY2874455 potently inhibits FGFR gatekeeper mutants and overcomes mutation-based resistance
Daichao Wu et al.
CHEMICAL COMMUNICATIONS (2018)
Determining Cysteines Available for Covalent Inhibition Across the Human Kinome
Zheng Zhao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Remarkably Stereospecific Utilization of ATP α,β-Halomethylene Analogues by Protein Kinases
Feng Ni et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2017)
H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma
Jaya Julie Joshi et al.
CANCER RESEARCH (2017)
Mechanism of FGF receptor dimerization and activation
Sarvenaz Sarabipour et al.
NATURE COMMUNICATIONS (2016)
Crystal Structure of the FGFR4/LY2874455 Complex Reveals Insights into the Pan-FGFR Selectivity of LY2874455
Daichao Wu et al.
PLOS ONE (2016)
Targeting FGFR Signaling in Cancer
Mehdi Touat et al.
CLINICAL CANCER RESEARCH (2015)
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
Margit Hagel et al.
CANCER DISCOVERY (2015)
DFG-out Mode of Inhibition by an Irreversible Type-1 Inhibitor Capable of Overcoming Gate-Keeper Mutations in FGF Receptors
Zhifeng Huang et al.
ACS CHEMICAL BIOLOGY (2015)
Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations
Han Kiat Ho et al.
DRUG DISCOVERY TODAY (2014)
The Fibroblast Growth Factor Receptor Genetic Status as a Potential Predictor of the Sensitivity to CH5183284/Debio 1347, a Novel Selective FGFR Inhibitor
Yoshito Nakanishi et al.
MOLECULAR CANCER THERAPEUTICS (2014)
High fibroblast growth factor 19 (FGF19) expression predicts worse prognosis in invasive ductal carcinoma of breast
Abdelbaset Buhmeida et al.
TUMOR BIOLOGY (2014)
Expression of Fibroblast Growth Factor 19 Is Associated with Recurrence and Poor Prognosis of Hepatocellular Carcinoma
Jiyeon Hyeon et al.
DIGESTIVE DISEASES AND SCIENCES (2013)
Pan-FGFR Inhibition Leads to Blockade of FGF23 Signaling, Soft Tissue Mineralization, and Cardiovascular Dysfunction
Gina M. Yanochko et al.
TOXICOLOGICAL SCIENCES (2013)
Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models
Dorothy M. French et al.
PLOS ONE (2012)
HKL-3000:: the integration of data reduction and structure solution -: from diffraction images to an initial model in minutes
Wladek Minor et al.
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY (2006)
分享论文
